p21^WAF1 Mutations and human malignancies

References

• Nigro J. M., Baker S. J., Presinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P., Glover T., Collins F. S., Weston A., Modali R., Harris C. C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–708
   PubMed Web of Science ®Google Scholar
• Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412–2421
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., III, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D., Harris C. C. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA 1994; 91: 11045–11049
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W. G., Reiter A., Ludwig W D., Zimmermann M., Scwaller J., Lee E., Miyoshi I., Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755–760
   PubMed Web of Science ®Google Scholar
• Hatta Y., Hirama T., Miller C. W., Yamada Y., Tomonaga M., Koeffler H. P. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699–2704
   PubMed Web of Science ®Google Scholar
• Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704
   PubMed Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino T., Velculescu V., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Noda A., Ning Y., Venable S. F., Pereira-Smith O. M., Smith J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res 1994; 211: 90–98
   PubMed Web of Science ®Google Scholar
• Sherr C. J. GI phase progression: Cycling on cue. Cell 1994; 79: 551–555
   PubMed Web of Science ®Google Scholar
• Nurse P. Ordering S phase and M phase in the cell cycle. Cell 1994; 79: 547–550
   PubMed Web of Science ®Google Scholar
• Morgan D. O. Principles of CDK regulation. Nature 1995; 374: 131–134
   PubMed Web of Science ®Google Scholar
• Kato J., Matsuoka M., Strom D. K., Sherr C. J. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell Biol 1994; 14: 2713–2721
   PubMed Web of Science ®Google Scholar
• Fisher R. P., Morgan D. O. A novel cyclin associates with Mo15/CDK7 to form the CDK-activating kinase. Cell 1994; 78: 713–724
   PubMed Web of Science ®Google Scholar
• Makela T. P., Tassan J. P., Nigg E. A., Frutiger S., Hughes G. J., Weinberg R. A. A cyclin associated with the CDK-activating kinase MO15. Nature 1994; 371: 254–257
   PubMed Web of Science ®Google Scholar
• Sherr C. J. Mammalian GI cyclins. Cell 1993; 73: 1059–1065
   PubMed Web of Science ®Google Scholar
• Xiong Y., Zhang H., Beach D. D-type cyclins associates with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505–514
   PubMed Web of Science ®Google Scholar
• Meyerson M., Harlow E. Identification of a GI kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol 1994; 14: 2077–2086
   PubMed Web of Science ®Google Scholar
• Matsushime H., Roussel M. F., Ashmun R. A., Sherr C. J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991; 65: 701–713
   PubMed Web of Science ®Google Scholar
• Dulic V., Lees E., Reed S. I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992; 257: 1958–1961
   PubMed Web of Science ®Google Scholar
• Girard F., Strausfeld U., Fernandez A., Lamb N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991; 67: 1169–1179
   PubMed Web of Science ®Google Scholar
• Nevins J. R. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424–429
   PubMed Web of Science ®Google Scholar
• Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–707
   PubMed Web of Science ®Google Scholar
• Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257–261
   PubMed Web of Science ®Google Scholar
• Guan K., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Matera A. G., Xiong Y. Growth suppression by p18, a p16INK4/MTS1and p15INK4/MTS2related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Hirai H., Roussel M. F., Kato J., Ashmun R. A., Sherr C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell Biol 1995; 15: 2672–2681
   PubMed Web of Science ®Google Scholar
• Gu Y., Turck C. W., Morgan D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory sub-unit. Nature 1993; 366: 707–710
   PubMed Web of Science ®Google Scholar
• Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59–66
   PubMed Web of Science ®Google Scholar
• Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74
   PubMed Web of Science ®Google Scholar
• Lee M. H., Reynisdottir I., Massague J. Cloning of p57Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639–649
   PubMed Web of Science ®Google Scholar
• Matsuoka S., Edwards M., Bai C., Parker S., Zhang P., Baldini A., Harper J. W., Elledge S. J. p57KIP2, a structually distinct member of the p21 CIPI cdk inhibitory family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650–662
   PubMed Web of Science ®Google Scholar
• Kato J-Y., Matsuoka M., Polyak K., Massague J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496
   PubMed Web of Science ®Google Scholar
• Polyak K., Kato J-Y., Solomon M., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9–22
   PubMed Web of Science ®Google Scholar
• Zhang H., Xiong Y., Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell 1993; 4: 897–906
   PubMed Web of Science ®Google Scholar
• Xiong Y., Zhang H., Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572–1583
   PubMed Web of Science ®Google Scholar
• Chen J., Jackson P. K., Kirschner M. W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374: 386–388
   PubMed Web of Science ®Google Scholar
• Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159–161
   PubMed Web of Science ®Google Scholar
• Nakanishi M., Robetorye R. S., Adam G. R., Pereira-Smith O. M., Smith J. R. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP/WAF1. EMBO. J 1995; 14: 555–563
   PubMed Web of Science ®Google Scholar
• Goubin F., Ducommun B. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene 1995; 10: 2281–2287
   PubMed Web of Science ®Google Scholar
• Li R., Waga G., Hannon G. J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534–537
   PubMed Web of Science ®Google Scholar
• Shim J., Lee H., Park J., Kim H., Choi E J. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996; 381: 804–807
   PubMed Web of Science ®Google Scholar
• Li Y., Jenkins C. W., Nichols M. A., Xiong Y. Cell cycle expression and p53 regulation of the cyclindependent kinase inhibitor p21. Oncogene 1994; 9: 2261–2268
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y., Wiman K. G., Mercer W. E., Kastan M. B., Kohn K. W., Elledge S. J., Kinzler K. W., Vogelstein B. WAFT/CIP1 is induced in p53-mediated GI arrest and apoptosis. Cancer Res 1994; 54: 1169–1174
   PubMed Web of Science ®Google Scholar
• Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391–3395
   PubMed Web of Science ®Google Scholar
• Steinman R. A., Hoffman B., Iro A., Guillouf C., Liebermann D. A., El-Houseini M. E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9: 3389–3396
   PubMed Web of Science ®Google Scholar
• Jiang H., Lin J., Su Z-Z., Collart F. R., Huberman E., Fisher P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397–3406
   PubMed Web of Science ®Google Scholar
• Schwaller J., Koeffler H. P., Niklaus G., Loetscher P., Nagel S., Fey M. F., Tobler A. Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest 1995; 95: 973–979
   PubMedGoogle Scholar
• Macleod K. F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53- dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935–944
   PubMed Web of Science ®Google Scholar
• Shiohara M., Akashi M., Gombart A. F., Yang R., Koeffler H. P. Tumor necrosis factor α: Posttranscriptional stabilization of WAFT mRNA in p53-deficient human leukemic cells. J. Cell Physiol 1996; 166: 568–576
   PubMed Web of Science ®Google Scholar
• Datto M. B., Li Y., Panus J. F., Howe D. J., Xiong Y., Wang X F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 1995; 92: 5545–5549
   PubMed Web of Science ®Google Scholar
• Li C-Y., Suardet L., Little J. B. Potential role of WAFT/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem 1995; 270: 4971–4974
   PubMed Web of Science ®Google Scholar
• Zhang W., Grasso L., McClain C. D., Gambel A. M., Cha Y., Travali S., Deisseroth A. B., Mercer W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55: 668–674
   PubMed Web of Science ®Google Scholar
• Akashi M., Hachiya M., Osawa Y., Spirin K., Suzuki G., Koeffler H. P. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J. Biol. Chem 1995; 270: 19181–19187
   PubMed Web of Science ®Google Scholar
• Parker S. B., Eichele G., Zhang P., Rawls A., Sands A. T., Bradley A., Olson E. N., Harper J. W., Elledge S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024–1027
   PubMed Web of Science ®Google Scholar
• Guo K., Wang J., Andres V., Smith R. C., Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol. Cell Biol 1995; 15: 3823–3829
   PubMed Web of Science ®Google Scholar
• Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018–1021
   PubMed Web of Science ®Google Scholar
• Skapek S. X., Rhee J., Spicer D. B., Lassar A. B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995; 267: 1022–1024
   PubMed Web of Science ®Google Scholar
• Missero C., Calautti E., Eckner R., Chin J., Tsai L. H., Livingston D. M., Dotto G. P. Involvement of the cell-cycle inhibitor Cipl/WAFI and the EIA-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA 1995; 92: 5451–5455
   PubMed Web of Science ®Google Scholar
• Gartenhaus R. B., Wang P., Hoffmann P. Induction of the WAFT/CIPI protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA 1996; 93: 265–268
   PubMed Web of Science ®Google Scholar
• Upadhyay S., Li G., Liu H., Chen Y. Q., Sarkar F. H., Kim H R. C. bel-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res 1995; 55: 4520–4524
   PubMed Web of Science ®Google Scholar
• Wagner A. J., Kokontis J. M., Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 1994; 8: 2817–2830
   PubMed Web of Science ®Google Scholar
• Deng C., Zhang P., Harper J. W., Elledge S. J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684
   PubMed Web of Science ®Google Scholar
• Gorospe M., Holbrook N. J. Role of p21 in prostaglandin A2-mediated cellular arrest and death. Cancer Res 1996; 56: 475–-479
   PubMed Web of Science ®Google Scholar
• Shiohara M., Gombart A. F., Berman J. D., Koeffler H. P., manuscript in preparation
   Google Scholar
• Yang Z. Y, Perkins N. D., Ohno T., Nabel E. G., Nabel G. J. The p21 cyclin-dependent kinase inhibitor sup-presses tumorigenicity in vivo. Nature Medicine 1995; 1: 1052–1056
   PubMed Web of Science ®Google Scholar
• Chen Y. Q., Cipriano S. C., Arenkiel J. M., Miller F. R. Tumor suppression by p21WAF1. Cancer Res 1995; 55: 4536–4539
   PubMed Web of Science ®Google Scholar
• Shiohara M., El-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAFT mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784
   PubMed Web of Science ®Google Scholar
• Tenan M., Carrara F., DiDonato S., Finocchiaro G. Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CK1 gene in malignant gliomas. Int. J. Cancer 1995; 62: 115–117
   PubMed Web of Science ®Google Scholar
• Bhatia K., Fan S., Spangler G., Weintraub M., O'Connor P. M., Judde J. G., Magrath I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 1995; 55: 1431–1435
   PubMed Web of Science ®Google Scholar
• Hirano Y., Yamato K., Tsuchida N. A temperature sensitive mutant of the human p53. Va1138, arrests rat cell growth without induced expression of cipl/wafl/sdil after temperature shift-down. Oncogene 1995; 10: 1879–1885
   PubMed Web of Science ®Google Scholar
• Wang Q. M., Jones J. B., Studzinski G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the GI-S phase block induced by 1, 25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996; 56: 264–267
   PubMed Web of Science ®Google Scholar
• Guan K., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Matera A. G., Xiong Y. Growth suppression by p18, a p16INK4/MTS1-and p14INK4/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Hunter T., Pines J. Cyclins and cancer. II. cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J-P. J., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar